Godavari Drugs Ltd vs Kobo Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Godavari Drugs Ltd is ₹ 126.6 as of 06 May 15:30 . The P/E Ratio of Godavari Drugs Ltd changed from 8.4 on March 2021 to 15 on March 2025 . This represents a CAGR of 12.30% over 5 yearsThe P/E Ratio of Kobo Biotech Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Godavari Drugs Ltd changed from ₹ 34.45 crore on March 2021 to ₹ 65.86 crore on March 2025 . This represents a CAGR of 13.84% over 5 yearsThe Market Cap of Kobo Biotech Ltd changed from ₹ 17.63 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Godavari Drugs Ltd for the Dec '25 is ₹ 22.45 crore as compare to the Sep '25 revenue of ₹ 27.28 crore. This represent the decline of -17.71% The revenue of Kobo Biotech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Godavari Drugs Ltd for the Dec '25 is ₹ 2.75 crore as compare to the Sep '25 ebitda of ₹ 2.63 crore. This represent the growth of 4.56% The ebitda of Kobo Biotech Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Godavari Drugs Ltd changed from ₹ 1.63 crore to ₹ 0.76 crore over 6 quarters. This represents a CAGR of -39.87% The net profit of Kobo Biotech Ltd changed from ₹ -1.33 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of -100.00% The Dividend Payout of Godavari Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Kobo Biotech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Godavari Drugs Ltd

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India..
Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections.

About Kobo Biotech Ltd

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992.
Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited.
The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US.

FAQs for the comparison of Godavari Drugs Ltd and Kobo Biotech Ltd

Which company has a larger market capitalization, Godavari Drugs Ltd or Kobo Biotech Ltd?

Market cap of Godavari Drugs Ltd is 128 Cr while Market cap of Kobo Biotech Ltd is 6 Cr

What are the key factors driving the stock performance of Godavari Drugs Ltd and Kobo Biotech Ltd?

The stock performance of Godavari Drugs Ltd and Kobo Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Godavari Drugs Ltd and Kobo Biotech Ltd?

As of May 6, 2026, the Godavari Drugs Ltd stock price is INR ₹126.6. On the other hand, Kobo Biotech Ltd stock price is INR ₹2.71.

How do dividend payouts of Godavari Drugs Ltd and Kobo Biotech Ltd compare?

To compare the dividend payouts of Godavari Drugs Ltd and Kobo Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.